NAREB Partners

Institut Pasteur (IP)

Paris, France

Professor Brigitte Gicquel 


Role in NAREB

  • Coordinator of the project
  • Leader of WP1 Screening of candidate therapeutic molecules & WP8 Management and Coordination
  • Identification of the targets and natural resistance to leads identified for further coupling to nanoparticles
  • Study of the microbial and host responses to the drugs associateonot to nanoparticles

Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA)

Grenoble, France

Fabrice Navarro


Role in NAREB

  • Leader of WP2 design of smart nanocarriers with antibacterial activity.
  • Development of drug-loaded lipid-based nanoparticles for the controlled delivery to MDR-TB and MRSA infections.

University Utrecht (UU)

Utrecht, The Netherlands

René van Nostrum


Role in NAREB

  • Development of drug-loaded polyester nanoparticles for the controlled delivery to MDR-TB and MRSA infections.

PROCARTA Biosystems Limited (PROCARTA)

Norwich, United Kingdom

Michael Mc Arthur


Role in NAREB

  • Development of novel oligonucleotide antimicrobials to treat Gram-positive infections caused by MRSA and Mycobacterium tuberculosis.
  • Development of novel, nanoparticulate delivery systems.

Universidad de Zaragoza (UNIZAR)  

Zaragoza, Spain

Jose Ainsa & Jesus Martinez de la Fuente


Role in NAREB

  • Leader of WP3 Diagnostic and activity tests in vitro
  • Development of drug-loaded polysaccharidic-based nanoparticles for the controlled delivery to MDR-TB and MRSA infections
  • Cytotoxicity test of nanoparticles against cell lines in vitro.
  • Antimicrobial activity test of encapsulated drugs against S. aureus and M. tuberculosis in vitro.

Narodowy Instytut Lekow (NIL)

Warsaw, Poland

Waleria Hryniewicz & Joanna Empel


Role in NAREB

  • Creation and delivery of a collection of pan-susceptible and drug resistanS. aureus isolates.
  • Antimicrobial activity test of drug-containing nanoparticles with S. aureus.

Forschungszentrum Borstel (FZB)

Borstel, Germany

Ulrich Schaible


Role in NAREB

  • Bio-distribution and treatment efficacy studies of anti-TB drug-loaded nanoparticles in different murine TB models using in vivo and ex vivo bio-imaging and confocal microscopy.


Lyon, France

Andrea Tamellini & Abdessalem Rekiki


Role in NAREB

  • Leader of WP4 In vivo efficacy tests and biodistribution
  • Evaluation of in vivo efficacy and fluorescent imaging biodistribution of drug-loaded nanoparticles in murine MRSA models.
  • Evaluation of pre-clinical safety of drug-loaded nanoparticles on human leukocytes in vivo

Department of Health (DH-MHRA)

London, United Kingdom

Mei Mei Ho


Role in NAREB

  • Establishment and coordination of the Product Development Team for the management of the drug development process and identification of potential regulatry issues relevant along a preclinical tearly phase clinical development pathway.

GlaxoSmithKline Investigation y Desarrollo (GSK)

Madrid, Spain

Lluis Ballel-Pages & Pablo Gamallo


Role in NAREB

  • Anti-tubercular lead sourcing fonano-encapsulation.
  • In vivo efficacy evaluatioof drug-loaded nanoparticles in murine TB models.

CORIS BioConcept (CORIS)

Gembloux, Belgium

Pascal Mertens & Laetitia Avrain


Role of Coris in NAREB

  • Development of new diagnostic tests for detecting bacteria and resistance markers.
  • Evaluation of drug-loaded nanoparticles with quantitative PCR for specific bacteria detection.

Nanoimmunotech (NIT)


Daniel Perez


Role in NAREB

  • Leader of WP5 Safety of developed nanosystems.
  • Physicochemical and biological characterization of the nanoparticles: sterility and endotoxin content of the generated nanoparticles, interaction with cells to validate cell targeting and hemocompatibility to validate administration route, biodistribution assay of the drug-loaded nanoparticles in collaboration with SINTEF. 
  • Safety evaluation: Toxic profile in vitro and in vivo of the prototypes. In vivo experiment for immunotoxicity assessment.

Stiftelsen Sintef (SINTEF)


Ruth Schmid


Role in NAREB

  • Development of antibiotics-loaded poly(alkylcyanoacrylate)(PACA) nanoparticles for the controlled delivery to MDR-TB and MRSA infections.
  • Drug loading and drug release studies in complex media by MS-based methods.
  • Activity screening for MRSA drugs.
  • Activity tests with S. aureus biofilms.
  • Biodistribution of drug-loaded nanoparticles in tissues with MS-imaging.

Inserm Transfert (IT)

Paris, France

Barbara Cagniard


Role of IT in NAREB

  • Leader of WP7 Dissemination, exploitation, training.
  • Support to project management.

Kuecept Limited (KU)

Hertfordshire, United Kingdom

Mark Saunders & Cristina Freire


Role in NAREB

  • Leader of WP6 Translational regulatory aspects and Clinical development Plan
  • Development of I.V. formulations of selected drug-loaded nanoparticles for in vivo efficacy testing.
  • Coordination of the Clinical development Plan to prepare the transition from preclinical research to the clinical development program.

University of East Anglia (UEA)

Norwich, United Kingdom

Michael Mc Arthur

Role in NAREB

  • Testing of antimicrobial formulations in the Galleria mellonella model.

  • Non-clinical development of oligonucleotide antimicrobials to treat MRSA infections.


The NAREB project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 604237.